The impact of dexmedetomidine added to ropivicaine for transversus abdominis plane block on stress response in laparoscopic surgery: a randomized controlled trial

Abstract

BackgroundIntravenous dexmedetomidine is known to attenuate stress response in patients undergoing laparoscopic surgery. We investigated whether the addition of the highly selective alpha-2 adrenergic agonist dexmedetomidine into ropivacaine for ultrasound-guided transversus abdominis plane block could inhibit stress response during laparoscopic surgery, and determined the optimal dose of dexmedetomidine in it.MethodsOne hundred and twenty-five patients undergoing laparoscopic gynecological surgery were included in this prospective and randomized double-blind study. Patients received general anesthesia with or without a total of 60\u2009ml of 0.2% ropivacaine in combination with low (0.25\u2009μg/kg), medium (0.50\u2009μg/kg) or high dose (1.0\u2009μg/kg) of dexmedetomidine for the four-quadrant transversus abdominis plane block (n\u2009=\u200925). The primary outcomes were stress marker levels during the operation.ResultsOne hundred and twenty patients completed the study protocol. Dexmedetomidine added to ropivacaine for transversus abdominis plane block significantly reduced serum levels of cortisol, norepinephrine, epinephrine, interleukin-6, blood glucose, mean arterial pressure and heart rate in a dose-dependent manner (P\u2009<\u20090.05), accompanied with decreased anesthetic and opioid consumption during the operation (P\u2009<\u20090.05), but the high dose of dexmedetomidine induced higher incidences of bradycardia than low or medium dose of dexmedetomidine (P\u2009<\u20090.05).ConclusionThe addition of dexmedetomidine at the dose of 0.5\u2009μg/kg into ropivacaine for ultrasound-guided transversus abdominis plane block is the optimal dose to inhibit stress response with limited impact on blood pressure and heart rate in patients undergoing laparoscopy gynecological surgery.Trial registrationThis study was registered at www.chictr.org.cn on November 6th, 2016 (ChiCTR-IOR-16009753).